Tesamorelin and Visceral Fat Research: HIV Lipodystrophy, MASH and GH Axis Biology (UK 2026)

Tesamorelin is a synthetic GHRH analogue — the 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification that stabilises the molecule against DPP-IV degradation and extends its effective half-life. It is the only GHRH analogue with FDA approval — specifically for HIV-associated lipodystrophy (HAL) — making it the most clinically validated GHRH research compound available. Its approval and clinical data provide an exceptionally well-characterised pharmacological reference point for GHRH analogue biology, GH axis stimulation in disease states, and visceral adipose tissue research.

HIV Lipodystrophy: The Clinical Context

HIV lipodystrophy (also called HIV-associated lipodystrophy syndrome, HALS) is a metabolic complication seen in patients receiving antiretroviral therapy (ART), particularly older nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) regimens. It produces a characteristic body composition disorder: visceral fat accumulation (increased abdominal girth, buffalo hump), peripheral lipoatrophy (loss of subcutaneous fat in the face, limbs, and buttocks), and dyslipidaemia (elevated triglycerides and LDL cholesterol).

The mechanism of HALS includes mitochondrial toxicity from older NRTIs causing peripheral fat loss, and protease inhibitor interference with lipid metabolism causing central fat accumulation. The result is a highly stigmatising phenotype that significantly impacts quality of life, medication adherence, and cardiovascular risk.

GH axis dysfunction is central to the visceral fat accumulation component of HALS: HIV patients with lipodystrophy demonstrate reduced GH pulse amplitude and impaired GHRH responsiveness compared to HIV patients without lipodystrophy, creating a state of functional GH deficiency that allows visceral adiposity to accumulate. Tesamorelin addresses this by restoring GHRH signalling and normalising GH pulse amplitude — the physiological driver of visceral fat mobilisation.

FDA Approval Evidence

Tesamorelin (Egrifta) was approved by the FDA in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval was based on two Phase 3 randomised controlled trials (LPSS1 and LPSS2):

Both trials enrolled HIV-infected adults on stable ART with confirmed visceral adipose tissue (VAT) excess by CT scan. Tesamorelin 2 mg daily subcutaneous injection versus placebo over 26 weeks produced statistically significant and clinically meaningful reductions in VAT — approximately 15–18% reduction in VAT area by CT in treated patients versus minimal change in placebo. Trunk fat mass (by DEXA) was also significantly reduced. Triglyceride levels decreased significantly. IGF-1 levels normalised from below-normal baseline.

Critically: the visceral fat reduction was attributed to GHRH-mediated GH axis restoration rather than supraphysiological GH, since tesamorelin’s mechanism is stimulating endogenous pulsatile GH rather than providing exogenous GH. The resulting IGF-1 levels normalised to age-appropriate ranges rather than exceeding them — consistent with physiological GH axis restoration.

Mechanism: GHRH Receptor Stimulation and Visceral Fat Biology

Tesamorelin stimulates GHRHR on pituitary somatotrophs, restoring pulsatile GH secretion toward normal amplitude. GH’s lipolytic effects on visceral adipose tissue are the primary mechanism of VAT reduction:

GH activates hormone-sensitive lipase (HSL) in visceral adipocytes through cAMP-mediated signalling — promoting triglyceride hydrolysis and fatty acid release. Visceral adipose tissue expresses more GH receptors than subcutaneous fat and is more sensitive to GH’s lipolytic effects, explaining the selective VAT reduction without equivalent subcutaneous fat loss. GH also reduces de novo lipogenesis in visceral fat — limiting new fat synthesis while HSL-mediated lipolysis reduces existing stores.

The restored GH pulsatility is the key — continuous GH would produce receptor desensitisation; the pulsatile pattern that tesamorelin restores maintains GHR sensitivity and sustained lipolytic efficacy over months of treatment.

MASH (Metabolic Dysfunction-Associated Steatohepatitis) Research

Beyond HIV lipodystrophy, tesamorelin has been investigated for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) — advanced fatty liver disease associated with obesity, insulin resistance, and metabolic syndrome. The GH/IGF-1 axis is relevant to MASH: GH deficiency or reduced GH pulsatility promotes hepatic lipid accumulation, and restoring GH axis activity could reduce liver fat and hepatic inflammation.

A Phase 2 trial of tesamorelin in non-HIV, metabolically at-risk adults with MASH demonstrated significant reductions in liver fat content measured by MRI and improvements in liver enzyme levels — suggesting the GH axis restoration mechanism is effective in MASH beyond the HIV-specific lipodystrophy context. This finding opens broader metabolic disease research applications for GHRH analogue biology.

Cognitive Research in Older Adults

GH/IGF-1 signalling has neuroprotective and cognitive maintenance roles — IGF-1 promotes neuronal survival, synaptic plasticity, and neurogenesis in the hippocampus, and GH/IGF-1 decline with age is associated with cognitive deterioration. Tesamorelin has been studied in a randomised trial in older adults without HIV, examining whether GH axis restoration through GHRH analogue improves cognitive function.

The NeuroGAIN trial (tesamorelin in older adults with mild cognitive impairment, UCSF) found that tesamorelin improved executive function (attention and working memory tests) compared to placebo at 20 weeks — a finding consistent with GH/IGF-1 axis restoration supporting cognitive function in the age-related GH deficiency context. This cognitive research angle positions tesamorelin as relevant beyond metabolic disease to neurological ageing research.

Comparison with Sermorelin and CJC-1295

Tesamorelin is the full 44-amino-acid GHRH sequence (compared to sermorelin’s 29-amino-acid fragment) with a chemical modification for stability. Its longer sequence produces higher GHRHR binding affinity and a longer effective half-life than sermorelin (approximately 30–40 minutes after injection), while remaining a pulsatile GHRH stimulus rather than the sustained “bleed” of CJC-1295. For research comparing GHRH analogue pharmacology across peptide length and modification, tesamorelin provides the full-length reference.

Summary

Tesamorelin is the GHRH analogue with the deepest clinical evidence base — two positive Phase 3 trials producing FDA approval for visceral fat reduction in HIV lipodystrophy, Phase 2 MASH data showing hepatic fat reduction, and cognitive improvement data in aged adults. Its mechanism of restoring physiological pulsatile GH secretion (rather than providing exogenous GH) makes it the most translationally relevant GHRH research tool. For UK researchers working in visceral fat biology, metabolic liver disease, GH axis restoration pharmacology, or neuroendocrinology of ageing, tesamorelin provides a clinically validated, mechanistically coherent, and extremely well-characterised research compound.